ReviewCold Spring Harbor perspectives in medicine2012
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
Review in Cold Spring Harbor perspectives in medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Real-world safety and efficacy of lecanemab in the treatment of Alzheimer's disease: a systematic review and meta-analysis.Journal of neurology · 2026Pooled it
- Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024.F1000Research · 2025Article
- Pharmacogenomics for neurodegenerative disorders - a focused review.Frontiers in pharmacology · 2024Review
- Sex Differences in Alzheimer's Disease.Neurologic clinics · 2023Review
- Effect of Treadmill Exercise and Trans-Cinnamaldehyde against d-Galactose- and Aluminum Chloride-Induced Cognitive Dysfunction in Mice.Brain sciences · 2020Article
- Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Are Irreversible Inhibitors the Future?International journal of molecular sciences · 2020Review
- Epidemiology and Risk Factors of Alzheimer's Disease in Iran: A Systematic Review.Iranian journal of public health · 2019Review
- Article
- Late-onset Alzheimer Disease.Continuum (Minneapolis, Minn.) · 2019Review
- Hydroxyurea attenuates oxidative, metabolic, and excitotoxic stress in rat hippocampal neurons and improves spatial memory in a mouse model of Alzheimer's disease.Neurobiology of aging · 2018Article
- Article
- Recent Progress in the Pharmacotherapy of Alzheimer's Disease.Drugs & aging · 2017Review
- Markers of Alzheimer's Disease in Primary Visual Cortex in Normal Aging in Mice.BioMed research international · 2017Article
- Tanshinone IIA Alleviates the AD Phenotypes in APP and PS1 Transgenic Mice.BioMed research international · 2016Article
- Lavandula angustifolia extract improves deteriorated synaptic plasticity in an animal model of Alzheimer's disease.Iranian journal of basic medical sciences · 2015Article
- Human neural stem cells alleviate Alzheimer-like pathology in a mouse model.Molecular neurodegeneration · 2015Article
- Acetylcholinesterase inhibitor modifications: a promising strategy to delay the progression of Alzheimer's disease.Neural regeneration research · 2015Article
- Matrine improves cognitive impairment and modulates the balance of Th17/Treg cytokines in a rat model of Aβ1-42-induced Alzheimer's disease.Central-European journal of immunology · 2015Article
- Taurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer's disease.Scientific reports · 2014Article
- Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.International journal of molecular sciences · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
In this work we consider marketed drugs for Alzheimer disease (AD) including acetylcholinesterase inhibitors (AChE-Is) and antiglutamatergic treatment involving the N-methyl-d-aspartate (NMDA) receptor. We discuss medications and substances available for use as cognitive enhancers that are not approved for AD or cognitive impairment, and other neurotransmitter-related therapies in development or currently being researched. We also review putative therapies that aim to slow disease progression by mechanisms not directly related to amyloid or tau.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.